RT Journal Article
SR Electronic
T1 Relationship Between Hematological Toxicities During Maintenance Treatment and During Chemotherapy Before Maintenance Treatment in Patients With Platinum-sensitive Relapsed Ovarian Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3653
OP 3658
DO 10.21873/anticanres.16546
VO 43
IS 8
A1 MATSUOKA, HIROFUMI
A1 NAKAMURA, KEIICHIRO
A1 YORIMITSU, MASAE
A1 OGAWA, MARIKO
A1 KANEMORI, MIHO
A1 SUEOKA, KOTARO
A1 KOZAI, AYUMI
A1 NAKAMURA, HIROKO
A1 HARUMA, TOMOKO
A1 SHIROYAMA, YUKO
A1 HAYATA, YUU
A1 SUGII, HIROKAZU
A1 UEDA, AKIKO
A1 KURIHARA, SHUICHI
A1 URAYAMA, SAIKO
A1 SHIMIZU, MIYUKI
A1 MASUYAMA, HISASHI
YR 2023
UL http://ar.iiarjournals.org/content/43/8/3653.abstract
AB Background/Aim: To determine if maintenance treatment can be performed effectively and safely in patients with platinum-sensitive relapsed ovarian cancer. Patients and Methods: We carried out a multi-center study to investigate progression-free survival (PFS) and adverse events (AEs) in 229 patients receiving maintenance treatment for platinum-sensitive relapsed ovarian cancer. Results: The median PFS in the 229 patients with maintenance treatment was 14.0 months (95% confidence interval=10.3-17.6 months). The hematological toxicities included ≥grade 3 anemia in 33.2% of cases. Anemia during maintenance treatment was significantly more common than anemia during chemotherapy given before maintenance treatment (p<0.001). Anemia during chemotherapy prior to maintenance treatment significantly increased the risk of anemia during maintenance treatment, compared with other clinical features (p<0.001). Conclusion: Maintenance treatment can be performed safely and effectively in patients with platinum-sensitive relapsed ovarian cancer. Anemia during chemotherapy given before maintenance treatment significantly increased the risk of developing anemia during maintenance treatment in patients with platinum-sensitive relapsed ovarian cancer.